{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-092665","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.860414+00:00","generated_at":"2026-06-11T09:02:34.248739+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gilead reports EVOKE-02 Phase 2 data: SG+Pembro 56% ORR in 1L mNSCLC","bullets":["ORR 69% in PD-L1 TPS≥50% (Cohort A), 44% in <50% (Cohort B); overall ORR 56%.","Median DOR not reached; 6-month DOR rate 88% in both cohorts.","Any-grade TEAEs 100%, Grade≥3 70%; 1 treatment-related death (sepsis).","Data inadvertently posted early by IASLC; Gilead discloses via 8-K.","Phase 3 EVOKE-03 comparing SG+Pembro vs Pembro monotherapy is ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-092665","json":"https://secwatch.observer/filing/0001104659-23-092665.json","markdown":"https://secwatch.observer/filing/0001104659-23-092665.md","text":"https://secwatch.observer/filing/0001104659-23-092665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000110465923092665/0001104659-23-092665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000110465923092665/tm2323971d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:02:34.248739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}